Franck Potet
Research Subjects
Research Interests
Franck Potet has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Alfred L. George
Northwestern University Feinberg School of Medicine
3 shared publications - Alfred L GeorgeJr
Department of Pharmacology, Vanderbilt University, Nashville, TN
2 shared publications - Allison Gallucci
OmniAb, Inc, Durham, North Carolina
2 shared publications Gareth Young
GlaxoSmithKline (GSK), Collegeville, Pennsylvania
2 shared publicationsJonathan Theile
OmniAb, Inc, Durham, North Carolina
2 shared publicationsKatrina Yoger
OmniAb, Inc, Durham, North Carolina
2 shared publications
Latest Publications
- Open Access
- 5 May 2026
- Published by Elsevier in Molecular Pharmacology
- Vol. 108 (5-6) , 100125
Identification and characterization of selective inhibitors of Nav1.9 voltage dependent sodium channels
- 5 May 2026
- Published by Elsevier in Molecular Pharmacology
- Vol. 108 (5-6) , 100125
Open AccessIdentification and characterization of selective inhibitors of Nav1.9 voltage dependent sodium channels
- Open Access
- 21 August 2025
- Published by Elsevier in Molecular Pharmacology
- Vol. 107 (10) , 100072
Voltage sensor interaction site for a selective small molecule Nav1.1 sodium channel potentiator that enhances firing of fast-spiking interneurons
- 21 August 2025
- Published by Elsevier in Molecular Pharmacology
- Vol. 107 (10) , 100072
Open AccessVoltage sensor interaction site for a selective small molecule Nav1.1 sodium channel potentiator that enhances firing of fast-spiking interneurons
- Top Cited PapersOpen Access
- 14 August 2023
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 155 (10)
Epilepsy-associated SCN2A (NaV1.2) variants exhibit diverse and complex functional properties
Pathogenic variants in voltage-gated sodium (NaV) channel genes including SCN2A, encoding NaV1.2, are discovered frequently in neurodevelopmental disorders with or without epilepsy. SCN2A is also a high-confidence risk gene for autism spectrum disorder (ASD) and nonsyndromic intellectual disability (ID). Previous work to determine the functional consequences of SCN2A variants yielded a paradigm in which predominantly gain-of-function variants cause neonatal-onset epilepsy, whereas loss-of-function variants are associated with ASD and ID. However, this framework was derived from a limited number of studies conducted under heterogeneous experimental conditions, whereas most disease-associated SCN2A variants have not been functionally annotated. We determined the functional properties of SCN2A variants using automated patch-clamp recording to demonstrate the validity of this method and to examine whether a binary classification of variant dysfunction is evident in a larger cohort studied under uniform conditions. We studied 28 disease-associated variants and 4 common variants using two alternatively spliced isoforms of NaV1.2 expressed in HEK293T cells. Automated patch-clamp recording provided a valid high throughput method to ascertain detailed functional properties of NaV1.2 variants with concordant findings for variants that were previously studied using manual patch clamp. Many epilepsy-associated variants in our study exhibited complex patterns of gain- and loss-of-functions that are difficult to classify by a simple binary scheme. The higher throughput achievable with automated patch clamp enables study of variants with greater standardization of recording conditions, freedom from operator bias, and enhanced experimental rigor. This approach offers an enhanced ability to discern relationships between channel dysfunction and neurodevelopmental disorders.
- 14 August 2023
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 155 (10)
Top Cited PapersOpen AccessEpilepsy-associated SCN2A (NaV1.2) variants exhibit diverse and complex functional properties
Pathogenic variants in voltage-gated sodium (NaV) channel genes including SCN2A, encoding NaV1.2, are discovered frequently in neurodevelopmental disorders with or without epilepsy. SCN2A is also a high-confidence risk gene for autism spectrum disorder (ASD) and nonsyndromic intellectual disability (ID). Previous work to determine the functional consequences of SCN2A variants yielded a paradigm in which predominantly gain-of-function variants cause neonatal-onset epilepsy, whereas loss-of-function variants are associated with ASD and ID. However, this framework was derived from a limited number of studies conducted under heterogeneous experimental conditions, whereas most disease-associated SCN2A variants have not been functionally annotated. We determined the functional properties of SCN2A variants using automated patch-clamp recording to demonstrate the validity of this method and to examine whether a binary classification of variant dysfunction is evident in a larger cohort studied under uniform conditions. We studied 28 disease-associated variants and 4 common variants using two alternatively spliced isoforms of NaV1.2 expressed in HEK293T cells. Automated patch-clamp recording provided a valid high throughput method to ascertain detailed functional properties of NaV1.2 variants with concordant findings for variants that were previously studied using manual patch clamp. Many epilepsy-associated variants in our study exhibited complex patterns of gain- and loss-of-functions that are difficult to classify by a simple binary scheme. The higher throughput achievable with automated patch clamp enables study of variants with greater standardization of recording conditions, freedom from operator bias, and enhanced experimental rigor. This approach offers an enhanced ability to discern relationships between channel dysfunction and neurodevelopmental disorders.
- Open Access
- 1 November 2020
- Published by Elsevier in Molecular Pharmacology
- Vol. 98 (5) , 540-547
GS-967 and Eleclazine Block Sodium Channels in Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes
GS-967 and eleclazine (GS-6615) are novel sodium channel inhibitors exhibiting antiarrhythmic effects in various in vitro and in vivo models. The antiarrhythmic mechanism has been attributed to preferential suppression of late sodium current (INaL). Here, we took advantage of a throughput automated electrophysiology platform (SyncroPatch 768PE) to investigate the molecular pharmacology of GS-967 and eleclazine on peak sodium current (INaP) recorded from human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes. We compared GS-967 and eleclazine to the antiarrhythmic drug lidocaine, the prototype INaL inhibitor ranolazine, and the slow inactivation enhancing drug lacosamide. In human induced pluripotent stem cell-derived cardiomyocytes, GS-967 and eleclazine caused a reduction of INaP in a frequency-dependent manner consistent with use-dependent block (UDB). GS-967 and eleclazine had similar efficacy but evoked more potent UDB of INaP (IC50=0.07 and 0.6 µM, respectively) than ranolazine (7.8 µM), lidocaine (133.5 µM) and lacosamide (158.5 µM). In addition, GS-967 and eleclazine exerted more potent effects on slow inactivation and recovery from inactivation compared to the other sodium channel blocking drugs we tested. The greater UDB potency of GS-967 and eleclazine was attributed to the significantly higher association rates (KON) and moderate unbinding rate (KOFF) of these two compounds with sodium channels. We propose thatsubstantial UDB contributes to the observed antiarrhythmic efficacy of GS-967 and eleclazine. Significance Statement We investigated the molecular pharmacology of GS-967 and eleclazine on sodium channels in human induced pluripotent stem cell derived cardiomyocytes using a high throughput automated electrophysiology platform. Sodium channel inhibition by GS-967 and eleclazine has unique features including accelerating the onset of slow inactivation and impairing recovery from inactivation. These effects combined with rapid binding and moderate unbinding kinetics explain potent use-dependent block, which we propose contributes to their observed antiarrhythmic efficacy.
- 1 November 2020
- Published by Elsevier in Molecular Pharmacology
- Vol. 98 (5) , 540-547
Open AccessGS-967 and Eleclazine Block Sodium Channels in Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes
GS-967 and eleclazine (GS-6615) are novel sodium channel inhibitors exhibiting antiarrhythmic effects in various in vitro and in vivo models. The antiarrhythmic mechanism has been attributed to preferential suppression of late sodium current (INaL). Here, we took advantage of a throughput automated electrophysiology platform (SyncroPatch 768PE) to investigate the molecular pharmacology of GS-967 and eleclazine on peak sodium current (INaP) recorded from human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes. We compared GS-967 and eleclazine to the antiarrhythmic drug lidocaine, the prototype INaL inhibitor ranolazine, and the slow inactivation enhancing drug lacosamide. In human induced pluripotent stem cell-derived cardiomyocytes, GS-967 and eleclazine caused a reduction of INaP in a frequency-dependent manner consistent with use-dependent block (UDB). GS-967 and eleclazine had similar efficacy but evoked more potent UDB of INaP (IC50=0.07 and 0.6 µM, respectively) than ranolazine (7.8 µM), lidocaine (133.5 µM) and lacosamide (158.5 µM). In addition, GS-967 and eleclazine exerted more potent effects on slow inactivation and recovery from inactivation compared to the other sodium channel blocking drugs we tested. The greater UDB potency of GS-967 and eleclazine was attributed to the significantly higher association rates (KON) and moderate unbinding rate (KOFF) of these two compounds with sodium channels. We propose thatsubstantial UDB contributes to the observed antiarrhythmic efficacy of GS-967 and eleclazine. Significance Statement We investigated the molecular pharmacology of GS-967 and eleclazine on sodium channels in human induced pluripotent stem cell derived cardiomyocytes using a high throughput automated electrophysiology platform. Sodium channel inhibition by GS-967 and eleclazine has unique features including accelerating the onset of slow inactivation and impairing recovery from inactivation. These effects combined with rapid binding and moderate unbinding kinetics explain potent use-dependent block, which we propose contributes to their observed antiarrhythmic efficacy.
- Open Access
GS-967 and Eleclazine Block Sodium Channels in Human Induced Pluripotent Stem Cell-derived Cardiomyocytes
GS-967 and eleclazine (GS-6615) are novel sodium channel inhibitors exhibiting antiarrhythmic effects in various in vitro and in vivo models. The antiarrhythmic mechanism has been attributed to preferential suppression of late sodium current ( I NaL ). Here, we took advantage of a throughput automated electrophysiology platform (SyncroPatch 768PE) to investigate the molecular pharmacology of GS-967 and eleclazine on peak sodium current ( I NaP ) recorded from human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes. We compared GS-967 and eleclazine to the antiarrhythmic drug lidocaine, the prototype I NaL inhibitor ranolazine, and the slow inactivation enhancing drug lacosamide. In human induced pluripotent stem cell-derived cardiomyocytes, GS-967 and eleclazine caused a reduction of I NaP in a frequency-dependent manner consistent with use-dependent block (UDB). GS-967 and eleclazine had similar efficacy but evoked more potent UDB of I NaP (IC 50 =0.07 and 0.6 μM, respectively) than ranolazine (7.8 μM), lidocaine (133.5 μM) and lacosamide (158.5 μM). In addition, GS-967 and eleclazine exerted more potent effects on slow inactivation and recovery from inactivation compared to the other sodium channel blocking drugs we tested. The greater UDB potency of GS-967 and eleclazine was attributed to the significantly higher association rates (K ON ) and moderate unbinding rate (K OFF ) of these two compounds with sodium channels. We propose that substantial UDB contributes to the observed antiarrhythmic efficacy of GS-967 and eleclazine. SIGNIFICANCE STATEMENT: We investigated the molecular pharmacology of GS-967 and eleclazine on sodium channels in human induced pluripotent stem cell derived cardiomyocytes using a high throughput automated electrophysiology platform. Sodium channel inhibition by GS-967 and eleclazine has unique features including accelerating the onset of slow inactivation and impairing recovery from inactivation. These effects combined with rapid binding and moderate unbinding kinetics explain potent use-dependent block, which we propose contributes to their observed antiarrhythmic efficacy.
Open AccessGS-967 and Eleclazine Block Sodium Channels in Human Induced Pluripotent Stem Cell-derived Cardiomyocytes
GS-967 and eleclazine (GS-6615) are novel sodium channel inhibitors exhibiting antiarrhythmic effects in various in vitro and in vivo models. The antiarrhythmic mechanism has been attributed to preferential suppression of late sodium current ( I NaL ). Here, we took advantage of a throughput automated electrophysiology platform (SyncroPatch 768PE) to investigate the molecular pharmacology of GS-967 and eleclazine on peak sodium current ( I NaP ) recorded from human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes. We compared GS-967 and eleclazine to the antiarrhythmic drug lidocaine, the prototype I NaL inhibitor ranolazine, and the slow inactivation enhancing drug lacosamide. In human induced pluripotent stem cell-derived cardiomyocytes, GS-967 and eleclazine caused a reduction of I NaP in a frequency-dependent manner consistent with use-dependent block (UDB). GS-967 and eleclazine had similar efficacy but evoked more potent UDB of I NaP (IC 50 =0.07 and 0.6 μM, respectively) than ranolazine (7.8 μM), lidocaine (133.5 μM) and lacosamide (158.5 μM). In addition, GS-967 and eleclazine exerted more potent effects on slow inactivation and recovery from inactivation compared to the other sodium channel blocking drugs we tested. The greater UDB potency of GS-967 and eleclazine was attributed to the significantly higher association rates (K ON ) and moderate unbinding rate (K OFF ) of these two compounds with sodium channels. We propose that substantial UDB contributes to the observed antiarrhythmic efficacy of GS-967 and eleclazine. SIGNIFICANCE STATEMENT: We investigated the molecular pharmacology of GS-967 and eleclazine on sodium channels in human induced pluripotent stem cell derived cardiomyocytes using a high throughput automated electrophysiology platform. Sodium channel inhibition by GS-967 and eleclazine has unique features including accelerating the onset of slow inactivation and impairing recovery from inactivation. These effects combined with rapid binding and moderate unbinding kinetics explain potent use-dependent block, which we propose contributes to their observed antiarrhythmic efficacy.
- Open Access
- 1 February 2016
- Published by Elsevier in Biophysical Journal
- Vol. 110 (3) , 447a
Use-Dependent Block of Human Cardiac Sodium Channels by GS967
- 1 February 2016
- Published by Elsevier in Biophysical Journal
- Vol. 110 (3) , 447a
Open AccessUse-Dependent Block of Human Cardiac Sodium Channels by GS967
- 1 August 2015
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 8 (4) , 933-941
Intracellular Calcium Attenuates Late Current Conducted by Mutant Human Cardiac Sodium Channels
Background—: Mutations of the cardiac voltage-gated sodium channel ( SCN5A gene encoding voltage-gated sodium channel [Na V 1.5]) cause congenital long-QT syndrome type 3 (LQT3). Most Na V 1.5 mutations associated with LQT3 promote a mode of sodium channel gating in which some channels fail to inactivate, contributing to increased late sodium current ( I NaL ), which is directly responsible for delayed repolarization and prolongation of the QT interval. LQT3 patients have highest risk of arrhythmia during sleep or during periods of slow heart rate. During exercise (high heart rate), there is elevated steady-state intracellular free calcium (Ca 2+ ) concentration. We hypothesized that higher levels of intracellular Ca 2+ may lower arrhythmia risk in LQT3 subjects through effects on I NaL . Methods and Results—: We tested this idea by examining the effects of varying intracellular Ca 2+ concentrations on the level of I NaL in cells expressing a typical LQT3 mutation, delKPQ, and another SCN5A mutation, R225P. We found that elevated intracellular Ca 2+ concentration significantly reduced I NaL conducted by mutant channels but not wild-type channels. This attenuation of I NaL in delKPQ expressing cells by Ca 2+ was not affected by the CaM kinase II inhibitor KN-93 but was partially attenuated by truncating the C-terminus of the channel. Conclusions—: We conclude that intracellular Ca 2+ contributes to the regulation of I NaL conducted by Na V 1.5 mutants and propose that, during excitation–contraction coupling, elevated intracellular Ca 2+ suppresses mutant channel I NaL and protects cells from delayed repolarization. These findings offer a plausible explanation for the lower arrhythmia risk in LQT3 subjects during fast heart rates.
- 1 August 2015
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 8 (4) , 933-941
Intracellular Calcium Attenuates Late Current Conducted by Mutant Human Cardiac Sodium Channels
Background—: Mutations of the cardiac voltage-gated sodium channel ( SCN5A gene encoding voltage-gated sodium channel [Na V 1.5]) cause congenital long-QT syndrome type 3 (LQT3). Most Na V 1.5 mutations associated with LQT3 promote a mode of sodium channel gating in which some channels fail to inactivate, contributing to increased late sodium current ( I NaL ), which is directly responsible for delayed repolarization and prolongation of the QT interval. LQT3 patients have highest risk of arrhythmia during sleep or during periods of slow heart rate. During exercise (high heart rate), there is elevated steady-state intracellular free calcium (Ca 2+ ) concentration. We hypothesized that higher levels of intracellular Ca 2+ may lower arrhythmia risk in LQT3 subjects through effects on I NaL . Methods and Results—: We tested this idea by examining the effects of varying intracellular Ca 2+ concentrations on the level of I NaL in cells expressing a typical LQT3 mutation, delKPQ, and another SCN5A mutation, R225P. We found that elevated intracellular Ca 2+ concentration significantly reduced I NaL conducted by mutant channels but not wild-type channels. This attenuation of I NaL in delKPQ expressing cells by Ca 2+ was not affected by the CaM kinase II inhibitor KN-93 but was partially attenuated by truncating the C-terminus of the channel. Conclusions—: We conclude that intracellular Ca 2+ contributes to the regulation of I NaL conducted by Na V 1.5 mutants and propose that, during excitation–contraction coupling, elevated intracellular Ca 2+ suppresses mutant channel I NaL and protects cells from delayed repolarization. These findings offer a plausible explanation for the lower arrhythmia risk in LQT3 subjects during fast heart rates.
- 1 January 2015
- Published by Elsevier in Biophysical Journal
- Vol. 108 (2) , 576a
Nav1.5 C-Terminal Domains Influence Calcium Regulation of Fast Inactivation Separately from Calmodulin Interaction
- 1 January 2015
- Published by Elsevier in Biophysical Journal
- Vol. 108 (2) , 576a
Nav1.5 C-Terminal Domains Influence Calcium Regulation of Fast Inactivation Separately from Calmodulin Interaction
- 1 June 1996
- Published by Wolters Kluwer Health in Diagnostic Molecular Pathology
- Vol. 5 (2) , 136-146
Improved Detection of Human Papillomavirus Infection in Genital Intraepithelial Neoplasia in Human Immunodeficiency Virus Positive (HIV +) Women by Polymerase Chain Reaction-In Situ Hybridization
The prevalence of genital human papillomavirus (HPV) infection was evaluated in 30 consecutive human immunodeficiency virus (HIV) + women by polymerase chain reaction (PCR)-in situ hybridization (ISH) on paraffin-embedded tissue sections and compared with that found with standard ISH. Biopsies were removed from normal or neoplastic areas in the cervix, vagina, and vulva, and ISH was performed with biotinylated or fluorescein isothiocyanate genomic DNA probes. One probe was used for HPV screening and others for HPV typing (types 6, 11, 16, 18, 31, and 33). Sequences were amplified by the “hot-start” PCR method and followed by standard ISH. Among the 30 HIV + women, 90% scored HPV + in one or several locations by PCR-ISH, whereas only 67% were positive by ISH. Oncogenic HPV types were found in 63% by PCR-ISH and in only 43% by ISH. The same HPV types detected by standard ISH were also recognized by PCR-ISH, but with the latter the signal was amplified. Moreover, some HPV types were found with PCR-ISH but not by ISH. We conclude that PCR-ISH is a valuable and sensitive method for specific detection of HPV.
- 1 June 1996
- Published by Wolters Kluwer Health in Diagnostic Molecular Pathology
- Vol. 5 (2) , 136-146
Improved Detection of Human Papillomavirus Infection in Genital Intraepithelial Neoplasia in Human Immunodeficiency Virus Positive (HIV +) Women by Polymerase Chain Reaction-In Situ Hybridization
The prevalence of genital human papillomavirus (HPV) infection was evaluated in 30 consecutive human immunodeficiency virus (HIV) + women by polymerase chain reaction (PCR)-in situ hybridization (ISH) on paraffin-embedded tissue sections and compared with that found with standard ISH. Biopsies were removed from normal or neoplastic areas in the cervix, vagina, and vulva, and ISH was performed with biotinylated or fluorescein isothiocyanate genomic DNA probes. One probe was used for HPV screening and others for HPV typing (types 6, 11, 16, 18, 31, and 33). Sequences were amplified by the “hot-start” PCR method and followed by standard ISH. Among the 30 HIV + women, 90% scored HPV + in one or several locations by PCR-ISH, whereas only 67% were positive by ISH. Oncogenic HPV types were found in 63% by PCR-ISH and in only 43% by ISH. The same HPV types detected by standard ISH were also recognized by PCR-ISH, but with the latter the signal was amplified. Moreover, some HPV types were found with PCR-ISH but not by ISH. We conclude that PCR-ISH is a valuable and sensitive method for specific detection of HPV.